Completed PHASE4 INTERVENTIONAL 2-arm NCT04806373

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis

Sponsor: Genentech, Inc.

Conditions Pleural Effusion

Interventions Cathflo Activase Talc Slurry Pleurodesis

Updated 9 times since 2021 Last updated: May 22, 2025 Started: Jun 15, 2021 Primary completion: Dec 14, 2023 Completion: Dec 14, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pleural Effusion, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 9 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Jul 2025 — Present [monthly]

Completed PHASE4
Jan 2025 — Jul 2025 [monthly]

Completed PHASE4
Sep 2024 — Jan 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2024 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 4 earlier versions

Nov 2023 — Apr 2024 [monthly]

Recruiting PHASE4
Sep 2022 — Nov 2023 [monthly]

Recruiting PHASE4
Oct 2021 — Sep 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Apr 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Memorial Healthcare System

Data source: Memorial Healthcare System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hollywood, United States